Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 451, 1066-1067 (28 February 2008) | doi:10.1038/4511066a; Published online 27 February 2008
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Group Leader Positions
- IMP
- Vienna Austria
Postdoctoral Associate in Enzyme Biochemistry
- Cornell University
- Ithaca, NY
Cancer: Crossing over to drug resistance
David M. Livingston1 & Daniel P. Silver1
Abstract
Certain cancers stem from mutations that prevent a cell from repairing its damaged DNA efficiently. But antitumour chemotherapy that exploits that repair defect can in turn be nullified by counter-mutation.
Two papers1, 2 in this issue provide insight into a subset of breast and ovarian cancers, the action of drugs used to treat them, and a novel mechanism of chemotherapeutic drug resistance. The papers are by Edwards et al.1 and Sakai et al.2, and appear on pages 1111 and 1116.
- David M. Livingston and Daniel P. Silver are at the Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA.
Email: david_livingston@dfci.harvard.edu
Email: daniel_silver@dfci.harvard.edu
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Bench to bedside BRCA: From therapeutic target to therapeutic shieldNature Medicine News and Views (01 May 2008)
